
Purdue Pharma was fined $643.5 million in 2007 for its part in creating the opioid epidemic that has plagued the …

Researchers in Japan have achieved a notable success in a Phase 3 clinical trial to determine whether a new vaccine …

The reaction from the pharmaceutical industry has been mixed since the announcement of serialisation requirements. Ben Hargreaves discovers the challenges …

Sanofi has revealed that it has agreed a deal with SK Chemicals, a South Korean vaccine manufacturer, to license its …

President Trump’s rhetoric leading up to his election had the pharmaceutical industry very worried – his often quoted line about …

MannKind, the California-based biotech, announced that David Kendall would be joining its team as Chief Medical Officer and would be …

A small titbit of information was buried within GSK’s financials this week, which threatens to bring up old news that …

Fujifilm has been steadily building up its regenerative medicines, with several acquisitions of companies that hold expertise in the area …

The cacophony of bad news that Teva has received in 2017 really needs no retelling, anyone following the story of …

Dr Reddy’s Laboratories problem with ensuring products reach the market at a quality the FDA deems acceptable is no secret …

Novartis had not been frontrunner to receive approval for its generic version of GSK’s Advair – lagging behind Mylan’s generic …

The JAK inhibitor field is beginning to heat up – AbbVie is soon to enter Phase 3 with its predicted …

Early in February, Arcturus Therapeutics revealed that it had let its CEO, Joseph Payne, go and had replaced him as …

Array Biopharma suffered a serious knock back in early 2017 when its plan to commercialise its drug, binimetinib, were derailed …

England is not alone in being particularly hard hit this flu season, with Australia suffering its worst flu season in …